Mutsa Tatenda Madondo

TL;DR: Enterococcus hirae and B. intestinihominis represent valuable "oncomicrobiotics" ameliorating the efficacy of the most common alkylating immunomodulatory compound CTX, and selectively predicted longer progression-free survival in advanced lung and ovarian cancer patients treated with chemo-immunotherapy.

TL;DR: Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management, but newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.

TL;DR: Tregs from tumor-associated ascites were the most potent suppressor T cell fraction and targeting TNFR2+ Tregs may offer new approaches to enhance the poor survival rates of ovarian cancer.

TL;DR: The potential for improving the efficacy of low dose cyclophosphamide is highlighted by combining insights on the mechanisms of cycloph phosphamide-mediated cytotoxicity, and how these cytotoxic effects of cyclphosphamide influence T cell function, thereby contributing to anti-tumour immunity.

TL;DR: Functionally, TNFR2+ Treg frequency was inversely correlated with interferon-gamma (IFN-γ) production by effector T cells, and was uniquely able to suppress TNFR 2+ T effectors.